Last Updated on June 13, 2019 by Sultan Beardsley
Leave a comment and click here to subscribe for MS article alerts and our newsletter!
Adamis Pharmaceutical (NASDAQ: ADMP), a speciality pharmaceutical company, upheld its commitment to file a new drug application (NDA) for its sublingual Tadalafil (Cialis) sublingual tablet by the years end.
Erectile dysfunction affects nearly 70% of men in their 70’s and 40% of men at age 40. It’s market value is expected to reach $3.2 by 2022. The elephant in the room now is where is Naloxone NDA also purported to be filed before 2019? Given the NDA for the sublingual Taladafil tablet was done on December 28th, 2018, we may find out in a the next day or so that the Naloxone NDA was filed sometime between the 29th and 31st of this month. If not, I am sure we can expect it soon. There is a huge Naloxone market, with limited competition, for ADMP to penetrate.
At the moment, Narcan is the only product fulfilling the antidotal need to reverse overdoses. ADMP’s naloxone pre-filled syringe uses the same proprietary symject technology as the Symjepi epinephrine products. Therefore, it stands to reason odds of approval are about the same as they were for Symjepi .15 mg. For now lets wait and be patient. Another NDA may unveiled in the very near future. I know from conversations with Mr. Flathers the head of IR for ADMP, the Naloxone pre-filled syringe is the product he is most excited about.